Due to the thrombogenic surface, platelet function-inhibiting drugs are needed to prevent in-stent thrombosis. The current solution of preventing platelet activation is the Dual Anti-Platelet Therapy (DAPT) consisting of Aspirin and Clopidogrel.

phenox Inc. offers innovative medical devices and solutions for neurovascular treatment.

Since its founding in 2005, phenox has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of neurovascular diseases.

HPC prevents the triggering of the clotting cascade and reduces the risk of thrombus formation on phenox neurovascular implants ; HPC mimics the glycocalix, thus the platelets do not recognize the surface as a foreign body. Systemic blood coagulation is not disturbed.

In April 2022, Wallaby Medical successfully acquired phenox GmbH (hereinafter referred to as "phenox"), a leading global neurointerventional company based in Germany.

Since its founding in 2005, phenox has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of neurovascular diseases....

Wä:. EMEA; Greater China; Central & South America; Japan; North America; Pacific Rim; EMEA; Manufacturing - Shanghai; R&D - Laguna Hills

2022年4月21日 · Since its foundation in 2005, phenox has developed into a global innovation leader in neurovascular devices for the interventional treatment of strokes. The company has a broad...

2022年4月21日 · The broadened product portfolio, enhanced R&D capability and expanded geographic coverage will provide Wallaby-phenox with an unparalleled competitive edge as we strive to become a global leader in the neurovascular market.”

February 2, 2023—Phenox Inc., a Wallaby Medical company, announced that its Preset thrombectomy device has received FDA clearance for use to treat acute ischemic stroke in the United States. The Preset product family has been available in Europe for more than 10 years.